Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Crovalimab versus eculizumab in PNH patients currently treated with complement inhibitors
2020-000597-26Phase 3Active
- Sponsor
- Roche
- Start
- Jun 2020
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of crovalimab in paroxysmal nocturnal hemoglobinuria (PNH) (2 arms), sponsored by Roche. Primary endpoint: Incidence and severity of adverse events. Started Jun 2020; status: active.
02
Drugs
crovalimab
03
Conditions
paroxysmal nocturnal hemoglobinuria (PNH)
Beyond the preview
Go deeper on 2020-000597-26.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2020-000597-26.